ULCIRON-O​ ​SYRUP

Indications

• Acute poisoning
• Drug overdose
• Gastrointestinal decontamination

Dosage

Children: Refer to specific pediatric dosing recommendations based on the child's weight and the clinical situation.

Adults: Refer to specific guidelines depending on the type of poisoning and the clinical scenario.

Mechanism of action

Activated charcoal works through a process called adsorption, where toxins and drugs adhere to the surface of the charcoal particles due to electrostatic attractions and Van der Waals forces. This prevents the absorption of these substances in the gastrointestinal tract, allowing them to be excreted from the body.

Pharmacodynamics

The pharmacodynamic effects of activated charcoal are related to its ability to bind a wide range of substances. The efficacy of activated charcoal varies depending on the type and amount of the toxin or drug ingested, as well as the time elapsed since ingestion. Generally, activated charcoal is most effective when administered within one hour of ingestion of a toxic substance.

Pharmacokinetics

Activated charcoal is not absorbed by the gastrointestinal tract; instead, it remains in the gut, where it binds to ingested substances and promotes their elimination via feces. Its effects are dose-dependent, and it is typically administered as a single dose, although multiple doses may be considered in certain cases of severe poisoning.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Aspiration pneumonia (if inhaled)
• Electrolyte imbalances

Precautions

• Use with caution in patients with gastrointestinal obstruction
• Monitor for potential aspiration in patients with reduced consciousness
• Consider electrolyte levels in patients with significant diarrhea or vomiting

Pregnancy

Activated charcoal is generally considered safe for use in pregnancy, but consult a healthcare professional before use.

Breast-feeding

Activated charcoal is excreted in breast milk, use with caution and consult a healthcare professional.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Activated charcoal powder
• Activated charcoal capsules
• Activated charcoal tablets

Indications

• Dyspepsia
• Peptic ulcer disease
• Gastroesophageal reflux disease (GERD)
• Heartburn
• Diarrhea
• Mucosal irritations

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations based on the condition being treated.

Mechanism of action

Aluminum acts as an astringent, causing local shrinkage or constriction of body tissues through osmotic flow of fluids away from the area of application. This mechanism assists in reducing mucous secretions and managing conditions such as peptic ulcers and diarrhea. Additionally, it can help in drying and hardening of tissues when applied topically.

Pharmacodynamics

Aluminum-based antacids work by neutralizing gastric acid, leading to an increase in gastric pH. This action helps to alleviate symptoms associated with excess gastric acid, such as heartburn and discomfort. The astringent properties of aluminum also contribute to its therapeutic effects in managing mucosal irritations and secretions.

Pharmacokinetics

Aluminum is absorbed minimally when taken orally, with a bioavailability of about 0.1 to 0.5%. The majority of aluminum is excreted renally, and its half-life can be prolonged in individuals with renal impairment. Long-term use may lead to accumulation and potential toxicity, particularly impacting bone and neurological health.

Interactions

• aluminiumhydroxide+deferasirox: Severe (decreases exposure)
• aluminiumhydroxide+enteralfeeds: Unknown (increases risk of blocked enteral or nasogastric tubes)
• aluminiumhydroxide+roxadustat: Unknown (decreases exposure)

Pregnancy

Aluminum compounds are generally considered safe in pregnancy when used as directed. However, excessive exposure should be avoided.

Breast-feeding

Aluminum is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• aluminium hydroxide suspension
• aluminium hydroxide tablets

Indications

• Dry skin
• Skin irritation
• Eczema
• Dermatitis
• Cosmetic applications as a moisturizer and thickening agent

Dosage

Children: Refer to specific product guidelines as dosing can vary based on formulation and intended use.

Adults: Refer to specific product guidelines as dosing can vary based on formulation and intended use.

Mechanism of action

Dimethicone works by forming a protective layer on the skin, which helps to seal in moisture and protect the skin from irritants. Its anti-foaming properties are due to its ability to reduce surface tension, allowing gas bubbles to coalesce and escape more easily, thus diminishing the formation of foam in solutions.

Pharmacodynamics

Dimethicone exhibits emollient properties, which means it can soften and soothe the skin. It acts by creating a barrier that prevents transepidermal water loss, thereby enhancing hydration. Its non-irritating nature makes it suitable for sensitive skin, and it does not clog pores, making it a preferred choice in many dermatological preparations.

Pharmacokinetics

Dimethicone is not absorbed systemically; it remains on the skin surface and does not penetrate into the deeper layers of the skin. This characteristic makes it effective as a topical agent. Because it is not metabolized or excreted by the body, its pharmacokinetic profile is primarily focused on its local effects rather than systemic absorption.

Adverse effects

• Allergic reactions
• Skin irritation
• Gastrointestinal discomfort

Precautions

• Use with caution in patients with a history of allergic reactions to silicone-based compounds
• Monitor for any signs of adverse reactions during treatment

Pregnancy

Dimethicone is generally considered safe for use during pregnancy, as it is not absorbed systemically.

Breast-feeding

Dimethicone is considered safe for use during breastfeeding, as it is not absorbed and is unlikely to affect breastfed infants.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Topical creams
• Lotions
• Ointments
• Oral suspensions

Indications

• Nutritional supplementation
• Herbal therapy for various conditions
• Preservation of medicinal properties of plants

Dosage

Children: Dosage for dried herbal preparations in children should be approached cautiously and is best determined by a healthcare professional. Refer to paediatric guidelines for specific dosing recommendations.

Adults: Dosage for dried herbal preparations varies widely depending on the specific herb and its intended use. Refer to specific guidelines or reputable sources for dosing information.

Mechanism of action

The mechanism of action for dried herbal preparations varies depending on the specific plant material involved. Generally, the active constituents in dried herbs can exert their effects through various pathways, such as modulating neurotransmitter systems, influencing metabolic pathways, and acting on specific receptors in the body. For instance, flavonoids, terpenes, and alkaloids found in certain dried herbs can exhibit anti-inflammatory, antioxidant, or antimicrobial properties.

Pharmacodynamics

The pharmacodynamics of dried drugs depend on their specific chemical constituents. These compounds can affect physiological functions, such as modulating inflammatory responses, enhancing immune function, or affecting neurotransmission. The effects can vary widely based on the type of herb, the method of drying, and the concentration of active ingredients.

Pharmacokinetics

The pharmacokinetics of dried herbal preparations can vary significantly based on the specific herb used. Generally, after ingestion, the active compounds are absorbed in the gastrointestinal tract, metabolized primarily by the liver, and then excreted through urine or feces. The bioavailability of these compounds can be influenced by factors such as the form of the preparation (e.g., powder, extract), the presence of other food substances, and individual patient characteristics.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

Consult a healthcare provider before use during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight.

Dosage

Children: Refer to specific guidelines for pediatric dosing; consult the BNF for Children for accurate dosage information.

Adults: Refer to specific guidelines for use; dosage may vary based on the context of use.

Mechanism of action

Hydroxide ions act primarily as bases, neutralizing acids to form water and salts. They participate in various biochemical pathways, including selenium metabolism and the degradation of reactive oxygen species. Hydroxide can influence enzyme activity and stability by altering the pH of the environment, thereby affecting metabolic reactions.

Pharmacodynamics

Hydroxide ions can impact biological processes by changing the local pH, which influences enzyme activity, ion transport, and the solubility of other compounds. Their ability to neutralize acids can help regulate physiological pH, contributing to homeostasis in living organisms.

Pharmacokinetics

As an inorganic ion, hydroxide does not undergo traditional pharmacokinetic processes like absorption, distribution, metabolism, or excretion. Instead, it is rapidly equilibrated in biological fluids and participates in acid-base reactions, having immediate effects on the local environment.

Pregnancy

There is limited information regarding the use of hydroxide during pregnancy. Consult a healthcare professional for advice.

Breast-feeding

Limited data is available on the excretion of hydroxide in breast milk. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Symptomatic relief of gastritis
• Management of peptic ulcers
• Treatment of hyperacidity-related symptoms

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric patients.

Adults: The dosage for adults should be determined based on the specific clinical scenario; refer to the BNF for detailed dosing recommendations.

Mechanism of action

Oxethazaine inhibits gastric acid secretion by suppressing gastrin secretion. It exerts a local anesthetic effect on the gastric mucosa by diminishing the conduction of sensory nerve impulses near the application site, which reduces the permeability of the cell membrane to sodium ions. This is facilitated by its weak base nature, allowing it to be relatively non-ionized in acidic solutions, thus penetrating cell membranes effectively.

Pharmacodynamics

Oxethazaine improves common gastrointestinal symptoms associated with hyperacidity and provides prolonged relief from pain at lower dosages. As part of the anesthetic antacids, it increases gastric pH while producing a reversible loss of sensation. Its local efficacy is significantly greater than that of traditional local anesthetics like lignocaine and cocaine. In vitro studies have shown its antispasmodic action on smooth muscle and its ability to block serotonin action, further contributing to its therapeutic effects.

Pharmacokinetics

Oxethazaine is absorbed locally at the site of application, with its effects lasting longer than typical local anesthetics due to its unique chemical properties. The metabolism and excretion pathways are not extensively documented. As a weak base, its solubility in organic solvents enhances its ability to penetrate tissues, improving its anesthetic effectiveness.

Adverse effects

• Nausea
• Vomiting
• Dizziness
• Headache
• Allergic reactions

Precautions

• Use with caution in patients with a history of hypersensitivity to local anesthetics
• Monitor for potential allergic reactions
• Avoid in patients with severe hepatic impairment

Pregnancy

Oxethazaine should only be used in pregnancy if the potential benefit justifies the potential risk to the fetus. Consult relevant guidelines.

Breast-feeding

It is not known whether oxethazaine is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store at room temperature, protected from light and moisture. Keep out of reach of children.

Formulations

• Oral suspension
• Topical gel

Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Excessive dietary aluminum has been proposed to be a factor contributing to several neurological disorders in humans. Six 8-week-old female Swiss Webster mice were fed for 10 wk purified diets containing 100 (control), 500 or 1000 ug aluminum/g diet. Brain and liver lipid peroxidation was determined by evaluating the production of 2-thiobarbituric acid reactive substances in brain and liver homogenates in the presence or absence of 50 uM ferrous iron. 2-Thiobarbituric acid reactive substances production in the absence of iron in brain homogenates from mice fed the 1000 ug/g diet was higher (30%) than that in the 100 ug/g control group (3.1 vs 2.4 nmol 2-thiobarbituric acid reactive substances/mg protein). The addition of ferrous iron increased 2-thiobarbituric acid reactive substances production in brain homogenates from all 3 dietary groups. The iron induced 2-thiobarbituric acid reactive substances production was 26% higher in the 1000 ug/g brain homogenates than in the 100 ug/g group (4.9 vs 3.9 nmol 2-thiobarbituric acid reactive substances/mg protein). Brain 2-thiobarbituric acid reactive substances production in the presence and absence of iron was similar between the 100 and 500 ug/g aluminum groups. 2-Thiobarbituric acid reactive substances production in liver homogenates measured either with or without iron was similar for the 3 groups. These results show that, in mice, dietary aluminum intoxication leads to increased brain 2-thiobarbituric acid reactive substance production, suggesting that enhanced lipid peroxidation may be one possible mechanism underlying the neurological damage associated with increased tissue aluminum. Evidence is presented indicating that dementias are associated with a relative insufficiency of magnesium in the brain. Such insufficiency may be attributable to low intake or retention of magnesium; high intake of a neurotoxic metal, such as aluminum, which inhibits activity of magnesium requiring enzymes; or impaired transport of magnesium and/or enhanced transport of the neurotoxic metal into brain tissue. It is proposed that Alzheimer's disease involves a defective transport process, characterized by both an abnormally high incorporation of aluminum and an abnormally low incorporation that an altered serum protein contributes to the progression of Alzheimer's disease by having a greater affinity for aluminum than for magnesium, in contrast to the normal protein, which binds magnesium better than aluminum. The altered protein crosses the blood-brain barrier more efficiently than the normal protein and competes with the normal protein in binding to brain neurons. Binding of the altered protein to the target neurons would both facilitate aluminum uptake and impede magnesium uptake. Evidence suggests that albumin is the serum protein that is altered. Aluminum is established as a neurotoxin, although the basis for its toxicity is unknown. It recently has been shown to alter the function of the blood-brain barrier, which regulates ex

Mechanism of action

Oxetacaine inhibits gastric acid secretion by suppressing gastrin secretion. Moreover, oxetacaine exerts a local anesthetic effect on the gastric mucosa. This potent local anesthetic effect of oxetacaine may be explained by its unique chemical characteristics in which, as a weak base, it is relatively non-ionized in acidic solutions whereas its hydrochloride salt is soluble in organic solvents and it can penetrate cell membranes. Oxetacaine diminishes the conduction of sensory nerve impulses near the application site which in order reduces the permeability of the cell membrane to sodium ions. This activity is performed by the incorporation of the unionized form into the cell membrane.

Pharmacodynamics

Oxetacaine improves common gastrointestinal symptoms. Oxetacaine is part of the anesthetic antacids which increase the gastric pH while providing relief from pain for a longer period of duration at a lower dosage. This property has been reported to relieve the symptoms of hyperacidity. Oxetacaine is reported to produce a reversible loss of sensation and to provide a prompt and prolonged relief of pain. In vitro, oxetacaine was showed to produce an antispasmodic action on the smooth muscle and block the action of serotonin. The local efficacy of oxetacaine has been proven to be 2000 times more potent than lignocaine and 500 times more potent than cocaine. Its anesthetic action produces the loss of sensation which can be explained by its inhibitory activity against the nerve impulses and de decrease in permeability of the cell membrane.